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are of 41% for this surgery and 30% for this medication, the remaining would choose 
neither of these treatments. CONCLUSIONS: The majority of women with SUI would       
like to be treated for their condition. If asked about their preferences for different 
treatment strategies, they tend to favour the nature of the treatment. Still, efﬁcacy and 
price issues are also taken into account.
PUK16
QUALITY OF LIFE OF ENTERIC-COATED MYCOPHENOLATE SODIUM 
(EC-MPS) IN RENAL TRANSPLANT RECIPIENTS WITH 
GASTROINTESTINAL TRACT COMPLAINTS TO MYCOPHENOLATE 
MOFETIL (MMF). MYVIDA STUDY
Andrés I1, Font B1, Mora S1, Lahoz R1, Ortega F2
1Novartis Farmaceutica SA, Barcelona, Spain, 2Hospital Universitario Central de Asturias, 
Oviedo, Spain
OBJECTIVES: To assess the effect of conversion from MMF to EC-MPS on QoL in 
renal transplantation (RTx) recipients who need dose reduction due to GI symptoms. 
METHODS: Multicenter, open-label, MMF-controlled, 12-weeks trial. RTx patients 
taking MMF who had previously reported GI adverse events were randomized to 
EC-MPS (n  70, equimolar dose for 0–2 wk, dose optimization until maximum toler-
ated dose or 720 mg bid for 2–6 wk and maintenance dose for 6–12 wk); or continue 
MMF (n  64, same dose adjustment). Primary endpoint was Gastrointestinal Quality 
of Life Index (GIQLI); secondary endpoints were Gastrointestinal Symptom Rating 
Scale (GSRS), Psychological General Well-Being Index (PGWBI), Overall Treatment 
Effect (OTE) and optimization of doses of MPA. RESULTS: GIQLI scores were sig-
niﬁcantly better in EC-MPS groups at 12 wk (110.1 vs 97.2 points, p  0.0136). Mean 
adjusted scores were also signiﬁcantly in this group for all secondary scales used 
(GSRS: 36.3 vs 29.2 points, p  0.0017; PGWBI: 78.1 vs 72.4 points, p  0.0343). 
OTE evaluation of GI symptoms was signiﬁcantly better for the EC-MPS group 
(p  0.0145-patients and p  0.0006-physicians). The number of patients receiving 
intermediate doses of MPA (EC-MPS/720 mg–MMF/1000 mg) at 12 weeks was sig-
niﬁcantly higher in EC-MPS group (55.4% vs 27.4%, p  0.003). More patients with 
MMF were receiving low doses than with EC-MPS (35.6% vs 10.3%, p  0.0004). 
In MMF group a higher percentage of patients did not raise the dosage from baseline 
(23.5% for MMF and 8.9% for EC-MPS group, p  0.004). CONCLUSIONS: EC-
MPS improves gastrointestinal quality of life in renal transplant patients with GI 
complaints to MMF, as it allows an optimization of MPA dose without increasing 
GI-related symptom burden.
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PUK17
CHRONIC OPIOID THERAPY IN ELDERLY PATIENTS WITH IMPAIRED 
RENAL FUNCTION OR WITH A HIGH RISK OF KIDNEY FAILURE  
IN GERMANY
Biteeva I1, Kruse S2
1Janssen-Cilag, Neuss, NRW, Germany, 2Janssen-Cilag GmbH, Neuss, NRW, Germany
OBJECTIVES: Elderly patients with impaired renal function or with a risk of kidney 
failure due to diabetes mellitus (DM) or with hypertension are at risk for accumulation 
of metabolites from certain opioids as well as for drug-drug interactions (DDI) because 
of their multimorbidity. The purpose of this analysis is to analyze the share of patients 
treated with opioids prone to accumulation of metabolites (e.g. morphine) or DDI via 
CYP450 (e.g. oxycodone, tramadole) in Germany. METHODS: This study was per-
formed using retrospective longitudinal aggregated patient data from the IMS Disease 
Analyzer. All patients 65 years or older with at least one diagnosis of DM (ICD10 
E10-E14), hypertension (I10-I15), renal failure (N17-N19), glomerular disease (N00-
N08) or renal tubulo-interstitial disease (N10-N16) with at least two prescriptions of 
extended-release (ER) morphine, hydromorphone, oxycodone or tramadole in 2008 
were included. The “P450 Drug Interaction Table” of the Indiana University was used 
as the source for substances with potential DDI. RESULTS: A total of 6565 patients 
aged 65 years or more with at least two ER opioids prescriptions in 2008 met the 
criteria of the high risk group for DDI and metabolite accumulation because of 
impaired renal function/ risk of kidney failure. A total of 702 (10.7%) patients from 
this group were treated with morphine, 528 (8.0)% with hydromorphone, 1.603 
(24.4%) with oxycodone, 3.732 (56.8%) with tramadole. Fifty-two percent of patients 
treated with oxycodone and 44% of those treated with tramadole concomitantly 
received a systemic therapy with a potential risk of DDI. CONCLUSIONS: The major-
ity of patients were treated with an opioid prone to accumulation of metabolites or 
DDI that can cause additional costs. For this group of patients the choice of hydro-
morphone can possibly avoid these potential complications.
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PCV1
MISDIAGNOSIS AND MISTREATMENT OF A COMMON SIDE-EFFECT—
ACE INHIBITOR INDUCED COUGH
Vegter S, Boersma C, De Jong-van den Berg LTW
University of Groningen, Groningen, The Netherlands
OBJECTIVES: Angiotensin converting enzyme inhibitors (ACEi) are frequently pres-       
cribed for various cardiac and renal diseases. A common side-effect of these drugs is 
a persistent dry cough. Physicians who fail to recognise a dry cough to be ACEi related 
may attemp to treat it with antitussive agents, in stead of recommended ACEi substi-
tution. Prescription behaviour in the general population considering treatment of the 
side-effect with antitussive agents has not been studied before. METHODS: Drug 
dispensing data between 2000 and 2007 were retrieved from the IADB.nl database.  
A prescription sequence symmetry analysis was used to determine whether antitussive           
agents were prescibed more often following ACEi initiation than the other way 
around. A logistic regression model was ﬁtted to determine predictors.        RESULTS: A 
total of 1054 patients were incident users of both ACEi and antitussives within a            
half-year time span. There was an excess of patients being prescibed antitussive agents 
after ACEi initiation, adjusted Sequence Ratio 2.2 (CI: 1.9–2.4). Females were more 
likely to be prescribed antitussive agents following ACEi therapy initiation, Odds 
Ratio 1.4 (CI: 1.1–1.9), age and comedications were no signiﬁcant predictors. CON-
CLUSIONS: There was a signiﬁcant and clinically relevant excess of patients receiving           
antitussives after ACEi initiation. The results suggest that cough as a side-effect of 
ACEi is not recognized as being ACEi related or is symptomatically treated with 
antitussive agents in stead of ACEi substitution. The estimated frequency of antitussive 
treatment of ACEi induced dry cough is 15%. Further results will be presented on 
cost implications of unnecassary drug use and decreased ACEi therapy compliance.
PCV2
INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS 
WITH UNTREATED PRIMARY HYPERPARATHYROIDISM
Yu N, Leese GP, Donnan PT
University of Dundee, Dundee, UK
OBJECTIVES: Primary hyperparathyroidism (PHPT) is the third most common endo-
crine disorder, with the majority changed being asymptomatic. Parathyroidectomy 
(PTX), as the only deﬁnite treatment, is available to severe PHPT (~20%). We evalu-
ated the mortality and co-morbidities in patients with PHPT with aim to estimate 
long-term impact of those untreated patients on the health care system. METHODS: 
This is a retrospective population-based cohort study. Using a unique patient identiﬁer 
in Tayside, Scotland, electronic record-linkage enabled a dataset of PHPT patients to 
be created from an algorithm of biochemistry and nuclear scan records, hospital 
admission data and community based prescriptions. Three additional datasets were 
added in order to measure the mortality and co-morbidities in comparison with the 
general population using standardised mortality/morbidity ratios (SMRs) and stan-
dardised incidence ratios (SIRs). Patients were split into ‘mild’ and ‘aggressive’ groups 
broadly following the NIH criteria for PTX. RESULTS: During the decade of 1997 
to 2006, we identiﬁed 2299 patients (70.4% female), 1683 (73.2%) as having mild 
PHPT. A third of the aggressive PHPT patients (32.8%) had undergone PTX. We 
found an increased risk of all-cause mortality (SMR: 2.58, 95% CI (2.39–2.79)) 
as well as cardiovascular and cancer related deaths (SMR: 2.49 (2.21–2.80); 3.02 
(2.60–3.48) respectively) in all patients. The risk is similar between the mild and 
the unoperated aggressive groups, but slightly reduced in the operated group. Unoper-
ated patients (both mild and aggressive) were also associated with high risk of co-
morbidities, with renal disease being the highest. Surgery signiﬁcantly improved 
patients’ health outcomes. CONCLUSIONS: The population prevalence of PHPT 
has generally increased; incidence is greater in females and increases with age. 
Mortality and morbidity are similarly higher for patients with mild and unoperated 
aggressive PHPT. Surgery may be worth recommending to all patients, and further 
study of the cost-effectiveness of surgery and chemotherapy is planned.
PCV3
USE OF SPIRONOLACTONE IN THE TREATMENT OF CONGESTIVE 
HEARTH FAILURE
Lachaine J1, Beauchemin C2, Ramos É3
1University of Montreal, Montréal, QC, Canada, 2University of Montreal, Montreal, QC, 
Canada, 3Pﬁzer Canada Inc, Kirkland, QC, Canada
OBJECTIVES: Aldosterone plays an important role in the pathophysiology of conges-
tive heart failure (CHF). Blockade of aldosterone receptors by spironolactone substan-
tially reduces risk of morbidity and mortality among patients with CHF. However, 
beneﬁts of spironolactone are potentially limited by its treatment compliance and 
adverse events proﬁle, particularly hyperkalemia and gynecomastia. The purpose of 
this study was to estimate the use of spironolactone in patients with CHF, the inci-
dence of key adverse events and patients compliance to spironolactone. METHODS: 
This study was performed using data from the Quebec provincial medical and drug 
plans (RAMQ). Data on medical and pharmaceutical services from January 2000 to 
September 2008 were obtained from the RAMQ for patients who had a diagnosis of 
CHF (ICD-9 codes  4280–4289) during that period. Relative incidence of gyneco-
mastia and hyperkalemia was estimated for users and non users of spironolactone. 
Treatment adherence was estimated for initial users of spironolactone and compared 
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to adherence with ACE inhibitors, beta-blockers and ARBs. RESULTS: RAMQ data 
were obtained for a total of 82,018 patients with a diagnosis of CHF. Among these 
patients, 59.9% used an ACE inhibitor, 59.5% a beta-blocker, 28.4% an ARB. and 
12,344 (15.1%) had used spironolactone. Incidence of hyperkalemia (3.3% vs. 1.4%) 
and of gynecomastia (1.8% vs. 0.7%) was signiﬁcantly higher among spironolactone 
users compared to non users (p  0.001). Treatment compliance was signiﬁcantly 
lower with spironolactone compared to ACE inhibitors, beta-blockers and ARBs 
(45.6% vs. 56.1%, 59.7%, 57.0% respectively; p  0.001). Persistence to treatment 
over a one year period was also lower with spironolactone compared to ACE inhibi-
tors, beta-blockers and ARBs (50.7% vs. 64.5%, 70.4%, 66.3% respectively; 
p  0.001) CONCLUSIONS: Although the use of spironolactone may be beneﬁcial 
for patients with CHF, its usefulness is limited by the incidence of adverse events and 
its relatively poor treatment compliance.
PCV4
SIGNAL DETECTION OF BRADYCARDIA ASSOCIATED WITH 
ATENOLOL HYDROCHLORIDE
Kumar A1, Kachhadiya R2
1Cadila Pharmaceuticals, Ahmedabad, Gujarat, India, 2VSR, Ahmedabad, Ahmedabad, Gujarat, 
India
OBJECTIVES: To compute the frequency of the bradycardia associated with Atenolol 
Hydrochloride for possible toxic signal detection (SD) by extracting the data from the 
Canadian Adverse Drug Reaction Monitoring Program (CADRMP) ‘MedEffec’. 
METHODS: Appropriate statistical methods such as, Proportional Reporting Ratio 
(PRR); Reporting Odds Ratio (ROR); the Chi-Square (C2) statistic; Observed to 
Expected Ratio (O/E) and the Du Mouchel method were used for Adverse Drug Reac-
tion (ADR) signal detection. Signiﬁcance of C2 and other calculated statistics, e.g., PRR 
and ROR was based on a composite criterion of regulatory guidelines e.g. value q4.0 
for C2, and q3.0 for the rest to be considered as signal detection. RESULTS: The bra-
dycardia associated with Atenolol Hydrochloride was 8 (A) and bradycardia associ-
ated with all other antihypertensive medicines was 48 (C). All other adverse drug 
reactions (except bradycardia) caused by Atenolol Hydrochloride were 235 (B) and 
all other ADR (but not bradycardia) associated with all other antihypertensive medi-
cines (except Atenolol Hydrochloride) were 2593 (D). The value of PRR was 1.8134; 
Reporting Odds Ratio was 1.8390 and the C2 statistic value was 2.2915. The O/E 
ratio was 1.7047 and 1.6972 was the value of PRR calculated by the Du Mouchel 
method. CONCLUSIONS: Atenolol hydrochloride, a selective B1 receptor antagonist 
introduced in 1976 as a replacement for propranolol in the treatment of hypertension 
shows a number of serious and non-serious adverse drug reactions. Signal detection 
of bradycardia associated with Atenolol Hydrochloride was not found signiﬁcant by 
any of the statistical method. However, since the calculated statistics were consider-
able, albeit not signiﬁcant, the possibility of bradycardia-Atenolol Hydrochloride 
pairing should still be analyzed from larger databases.
PCV5
PERIODONTAL DISEASE, STATIN USE, AND CARDIOVASCULAR 
EVENTS
Misra A1, Hansen LG2, Chang S1
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Northwood, NH, USA
OBJECTIVES: To utilize an integrated medical-drug-dental claims database to under-
stand the relationship between periodontal disease, statin use, and cardiovascular 
disease (CAD) events. METHODS: Patients were selected from the 2005–2007 
MarketScan® Dental Database who had periodontal disease, based on diagnosis 
or dental procedure codes, and 12 months of continuous enrollment prior to the peri-
odontal disease diagnosis (index date). The Dental Database includes medical, phar-
macy, and dental records for 6.5 million patients. Patients were divided into two 
cohorts—treated and not treated with statins—and followed for 12 months for evi-
dence of CAD events. CAD patients were identiﬁed using ICD-9-CM diagnosis codes 
414.00–414.07 and 414.8–9. RESULTS: There were 157,915 patients identiﬁed having 
periodontal disease and meeting the enrollment criteria; 155,802 (98.7%) did not have 
a CAD event in the 12 months prior to the index date. Twenty-ﬁve percent (40,049) of 
patients with periodontal disease were on statins during this period. Post-periodontal 
diagnosis, the rate of CAD event was 0.42 percent (N  652) for statin-treated patients. 
The rate of CAD event post-periodontal diagnosis date was 1.16 percent (N  1808) 
for untreated patients. Controlling for differences in demographics and preexisting 
clinical conditions, patients not treated with statins prior to being diagnosed with peri-
odontal disease are 2.77 times more likely to have a CAD event in the following 12 
months than treated patients. CONCLUSIONS: Integrating dental claims with medical 
and drug claims provides an opportunity to follow a large cohort of patients and 
determine the relationships between oral and medical care and drug utilization. Statin 
treatment for an at-risk population with periodontal disease may mitigate the risk of 
a CAD event. A longer follow-up period will further elucidate this relationship.
PCV6
DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT 
CARDIOVASCULAR DISEASE EVENT RISK AMONG PRIMARY AND 
SECONDARY RISK DYSLIPIDEMIA MANAGED CARE PATIENTS IN THE 
UNITED STATES
Balu S1, Quimbo RA2, Cziraky MJ2, Simko RJ1
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Assess associations between the Deyo-Charlson comorbidity index 
(DCI) score and cardiovascular disease (CVD) event risk among primary (PR) and 
secondary risk (SR) dyslipidemia patients in a managed care setting. METHODS: A 
retrospective analysis of patients aged q18 years with laboratory results from a com-
plete ﬁrst lipid panel (index date) between January 1, 2002-February 28, 2005 was 
performed using an integrated managed care research database. Inclusion criteria were 
patients with minimum of 12 months pre- and post-index date follow-up, without 
lipid-modifying medication use at least 6 months prior to index date, and at least one 
of LDL-C, HDL-C, or TG at sub-optimal level per multiple national treatment 
guidelines. Associations between pre-index DCI score and 3-year CVD event risk was 
estimated between PR and SR patients using a multivariate logistic regression model 
after controlling for demographic and clinical variables. RESULTS: A total of 45,716 
patients were identiﬁed, 57.8% (n  26,407) were PR. Statistical signiﬁcance was 
observed between the 2 groups at baseline in terms of percent males (SR: 56.7% vs. 
48.3%: PR; p  0.0001), DCI score (SR: 0.16 o 0.43 vs. PR: 0.64 o 0.72; p  0.0001), 
LDL-C (SR: 129.4 o 35.1 vs. PR: 126.7 o 34.8 mg/dL; p  0.0001), HDL-C 
(SR: 42.0 o 11.2 vs. PR: 48.4 o 14.0 mg/dL; p  0.0001), and TG (SR: 179.1 o 79.3 
vs. PR: 161.1 o 79.1 mg/dL; p  0.0001). Regression analysis showed that every one 
unit increase in pre-index DCI score was associated with a 34% [Odds Ratio 
(OR): 1.34 (1.27–1.41); p  0.05] higher likelihood to experience a CVD event 
at 3 years among SR patients versus 32% [OR: 1.32 (1.20–1.46); p  0.05] for PR 
patients. CONCLUSIONS: SR dyslipidemia patients with a higher DCI score were 
associated with a higher CVD event risk versus PR patients. Further research on this 
association and subsequent impact on long-term clinical and economic outcomes is 
needed.
PCV7
ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX 
SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND 
ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG 
MANAGED CARE PATIENTS IN THE UNITED STATES
Balu S1, Quimbo R2, Cziraky MJ2, Simko RJ1
1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc., Wilmington, DE, USA
OBJECTIVES: Assess associations between the Deyo-Charlson index (DCI) score and 
annual cardiovascular disease (CVD) event risk and attributable total health care costs 
(THC) between patients initiating niacin extended-release (NER) plus simvastatin 
(NER/S) and simvastatin plus ezetimibe (S/E) ﬁxed-dose therapy among patients with 
prior CVD. METHODS: A retrospective analysis of patients aged q18 years newly 
initiating S/E or NER/S therapy (initial therapy of NER added to existing simvastatin 
therapy) between January 1, 2001-June 30, 2006 (index date) was performed using a 
large integrated managed care research database. Patients with a minimum of 12 
months pre- and post-index date follow-up and a diagnosis of CVD at some time 
during 12 months prior to index date were included. Associations between pre-index 
date DCI score, CVD event risk, and THC [sum of inpatient, emergency room, and 
outpatient visit costs] were estimated using Cox proportional hazards regression 
model and multivariate generalized linear model, respectively. RESULTS: A total of 
7065 study patients were identiﬁed initiating S/E (n  6513) or NER/S (n  552). 
NER/S patients were signiﬁcantly younger (58.5 o 9.2 years vs. 61.3 o 10.2 years; p 
 0.0001) and more likely to be male (85.1% vs. 67.9%; p  0.0001). Pre-index date 
DCI score (1.3 o 1.3 vs. 1.4 o 1.6; p  0.1018) was comparable between the two 
groups. Cox regression showed that every one unit increase in pre-index date DCI 
score was associated with a 27% [Hazard Ratio (HR): 1.27 (1.22–1.32); p  0.05] 
higher likelihood to experience a post-index CVD event. Multivariate regression 
showed that every one unit increase in pre-index date DCI score was associated with 
a 38% (Coefﬁcient: 1.38, 95% CI: 1.30–1.47; p  0.0001) increase in mean annual 
CVD THC. CONCLUSIONS: High-risk patients with prior CVD and with an increas-
ing DCI score were associated with a higher CVD event risk and total annual CVD-
attributable THC. Further studies on dyslipidemia treatment strategies on higher risk 
patients are warranted.
PCV8
PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH 
A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR 
DIABETES MELLITUS. THE PANDORA SURVEY—BELGIUM RESULTS
Wautrecht JC1, Guillaume M2, Thoeng J3, Matthys A4
1Erasm Hospital, Brussels, Belgium, 2CHU Charleroi, Charleroi, Belgium, 3St Elisabeth 
Hospital, Turnhout, Belgium, 4AstraZeneca Belgium, Brussels, Belgium
Despite substantial research showing that peripheral arterial disease (PAD) increases 
the risk for heart attack, stroke, amputation and other vascular-related conditions, 
PAD is potentially under-diagnosed and under-treated. Once diagnosed, research 
indicates that PAD merits aggressive management of all cardiovascular disease (CVD) 
risk factors. OBJECTIVES: The primary objective was to assess the prevalence of 
lower extremity PAD through Ankle-Brachial Index (ABI) measurement in patients at 
moderate CVD risk, with no overt vascular diseases nor diabetes mellitus. Secondary 
objectives included the prevalence and treatment of CVD risk factors and patient/phy-
sicians’ determinants for PAD under-diagnosis. METHODS: PANDORA Belgium was 
part of a non-interventional, cross-sectional, multi-centre study conducted in six 
European countries. Selection of general practitioners (GPs) was based on ABI mea-
surement training according ACC/AHA guidelines. RESULTS: A total of 119 GPs in 
Belgium recruited 1510 evaluable patients. The mean prevalence of asymptomatic 
PAD, deﬁned as ABI  0.90, was 7%, the lowest prevalence in the 6 countries (mean 
18%). Mean LDL-C for asymptomatic PAD patients was 125 mg/dl. Sixty-seven 
percent of untreated dyslipidemic subjects, diagnosed with asymptomatic PAD, had 
LDL-C  130 mg/dl. 32% of the Belgian patients were treated with statins. Patients 
